AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 12:57:29 2026-05-28 pm EDT			5-day change	1st Jan Change
1.120 ^USD	-.--%		-.--%	-22.76%

Jul. 01	AB Science, successful private placement
Jun. 30	AB Science S.A. announced that it has received ?2.294 million in funding	CI

Market Cap	60.81M 69.43M 56.01M 51.99M 98.73M 6.62B 100M 670M 261M 3.25B 261M 255M 11.27B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	60.81M 69.43M 56.01M 51.99M 98.73M 6.62B 100M 670M 261M 3.25B 261M 255M 11.27B	EV / Sales 2026 *	50.7x	EV / Sales 2027 *	46.8x
Free-Float	72.29%	Yield 2026 *	-	Yield 2027 *	-

Jul. 01	AB Science, successful private placement
Jun. 30	AB Science S.A. announced that it has received ?2.294 million in funding	CI
Jun. 29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
Jun. 29	AB Science completes Step 3 of a Phase 1 study
Jun. 18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
Jun. 18	AB Science Secures New U.S. Patent for Masitinib
Jun. 17	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
Jun. 10	AB Science presents new data on Masitinib
May. 17	AB Science S.A. announced that it has received $2.989368 million in funding	CI
May. 13	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
May. 03	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
Apr. 29	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
Apr. 29	AB Science announces successful capital increase

Jul. 01	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
Jun. 29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
Jun. 29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ
Jun. 17	AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042	GL
Jun. 09	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS	GL

AB Science Stock OTC Markets

Stocks

ABSCF

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

Jul. 01	AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2026
Jul. 01	Bourse : Schneider se renforce dans l'IA, Air Liquide investit pour SK Hynix, Nike déçoit
Jul. 01	AB Science, succès d'un placement privé
Jul. 01	AB Science annonce le succès d’un placement privé de 2,3 millions d’euros
Jul. 01	La Bourse s'habitue à tout

Current year	1.12	1.37
1 year	1.12	1.45
3 years	0	4.46
5 years	0	18.78
10 years	0	26.7

Manager	Title	Age	Since
Alain Moussy CEO	Chief Executive Officer	-	2001-07-10
Laurent Guy DFI	Director of Finance/CFO	-	2009-11-19
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	2018-03-31

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	2001-07-10
Patrick Moussy BRD	Director/Board Member	-	2011-09-19
Cécile de Guillebon BRD	Director/Board Member	64	2021-06-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-.--%	-.--%	-	-	69.43M
MERCK & CO., INC.	-2.15%	-2.01%	+56.65%	+13.45%	313B
MERCK KGAA	-0.11%	-2.66%	+30.73%	-2.42%	70.89B
HALOZYME THERAPEUTICS, INC.	+1.67%	+4.66%	+49.59%	+120.65%	9.58B
KYOWA KIRIN CO., LTD.	-0.77%	+4.93%	+8.41%	+3.43%	8.82B
BETTA PHARMACEUTICALS CO., LTD.	-5.79%	+6.58%	+18.45%	+30.79%	4.25B
SK BIOPHARMACEUTICALS CO., LTD.	-2.55%	-7.79%	-8.10%	+8.11%	4.29B
YUHAN CORPORATION	-1.14%	-5.69%	-34.65%	+26.00%	3.39B
SUPERNUS PHARMACEUTICALS, INC.	-1.69%	+0.94%	+47.72%	+59.97%	2.74B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+1.66%	+1.88%	+17.18%	-19.63%	2.22B
Average	-1.09%	+2.51%	+20.67%	+26.71%	46.59B
Weighted average by Cap.	-1.70%	+2.42%	+49.04%	+13.36%

	2026 *	2027 *
Net sales	1.2M 1.37M 1.11M 1.03M 1.95M 131M 1.97M 13.23M 5.15M 64.15M 5.15M 5.03M 222M	1.3M 1.48M 1.2M 1.11M 2.11M 142M 2.14M 14.33M 5.58M 69.5M 5.57M 5.45M 241M
Net income	-	-
Net Debt	-	-